| HOME >> BIOLOGY >> TECHNOLOGY |
Alzheimer's Disease
Chapter 5
CHI INSIGHT PHARMA REPORTS MONOCLONAL
ANTIBODIES SURVEY--JULY 2009
References
Company Index with Web Addreses
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment
Tables
Table 3.1. FDA-Approved Therapeutic Monoclonal Antibodies
Table 3.2. Unconjugated Monoclonal Antibodies in Clinical Trials for Cancer
Table 3.3. Conjugated Monoclonal Antibodies in Clinical Trials for Cancer
Table 3.4. Monoclonal Antibodies in Clinical Trials for Immunological Diseases
Table 3.5. Monoclonal Antibodies in Clinical Trials for Infectious Diseases
Table 3.6. Monoclonal Antibodies in Clinical Trials for Cardiovascular Diseases
Table 3.7. Other Therapeutic Monoclonal Antibodies in Clinical Development
Table 4.1. Worldwide Sales of Therapeutic Monoclonal Antibodies,2007 and 2008
Table 4.2. Estimated New Cancer Cases in United States, Total and Selected Types, 2009
Figures
Figure 1.1. Structure of an Antibody
Figure 2.1. Monoclonal Antibody Production
Figure 2.2. Antibody Engineering
Figure 2.3. Engineered Forms of Antibodies
Figure 1A. Please classify your organization
Figure 2A. Focus of Respondents' Organizations
Figure 3A. Professional Responsibilities of Respondents
Figure 4A. Changes in mAb Pipelines
Figure 5A. Magnitude of Increase in mAb Pipelines
Figure 6A. Recent Changes in Level of Activity Related to mAbs
Figure 7A. Future Changes in Level of Activity Related to mAbs
Figure 8A. Rate of New mAb Approvals
Figure 9A. Challenges to mAb Development
Figure 10A. Key Technologies
Figure 11A. Future Improvements to mAbs
Figure
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |